WEBSITE BSE:543524 NSE: RAINBOW Inc. Year: 1998 Industry: Hospital & Healthcare Services My Bucket: Add Stock
Last updated: 15:58
Rainbow Children’s Medicare Ltd is a multi-speciality obstetrics, paediatric and gynaecology hospital chain in India. The agency’s infant health offerings consist of general paediatrics, neonatalogy, surgical treatment, gastroenterology and liver sicknesses, haematology and oncology, psychology, dentistry, pulmonology, endocrinology, nephrology, nutrients, psychiatry, ENT, cardiology, radiology, physiotherapy and rehabilitation, orthopaedics, urology, ophthalmology, dermatology, allergy, neurosurgery, rheumatology, infectious diso...Read More
Rainbow Children’s Medicare Ltd is a multi-speciality obstetrics, paediatric and gynaecology hospital chain in India. The agency’s infant health offerings consist of general paediatrics, neonatalogy, surgical treatment, gastroenterology and liver sicknesses, haematology and oncology, psychology, dentistry, pulmonology, endocrinology, nephrology, nutrients, psychiatry, ENT, cardiology, radiology, physiotherapy and rehabilitation, orthopaedics, urology, ophthalmology, dermatology, allergy, neurosurgery, rheumatology, infectious disorder, and cranio-maxillofacial surgical procedure; extensive care unit, bone marrow transplant unit, anesthesia and pain control, kidney transplant, cochlear implant services; genetics and metabolic drug treatments; and laboratory, speech and language remedy, occupational therapy, paediatric and metabolic medication, developmental and behavioural paediatrics, cerebral palsy care offerings. Its women health services comprises obstetrics and gynaecology, painless delivery and labor, high risk being pregnancy and delivery, childbirth preparation lessons, vaginal birth after cesarean, breast feeding assist, well women checkup, urogynecology, pre-pregnancy health checkup, minimally invasive surgery, breast care, fetal medicinal drug, menopausal treatment, new-born care, ladies's nutrients, and diabetology. The business enterprise additionally gives fertility care offerings, inclusive of fertility remedy, ovulation induction, intracytoplasmic sperm injection treatment, investigation, intrauterine insemination, intracytoplasmic morphologically selected sperm injection, assisted hatching, cryopreservation, sperm and oocyte donor remedies, frozen embryo switch, surgical sperm retrieval, embryo donor remedies, reproductive surgery, pre-conception counselling, and andrology and urology. As of December 31, 2021, it operated 14 hospitals and three clinics in 6 towns with a total of 1500 beds. The enterprise incorporated in 1998 and is primarily based in Hyderabad, India. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹12617 Cr.
Stock P/E 51.7
P/B 7.9
Current Price ₹1242.3
Book Value ₹ 156.7
Face Value 10
52W High ₹1644.1
Dividend Yield 0.24%
52W Low ₹ 1008.8
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 333 | 336 | 341 | 330 | 417 | 398 | 370 | 353 | 445 | 445 |
| Other Income | 8 | 9 | 13 | 12 | 11 | 13 | 15 | 20 | 8 | 11 |
| Total Income | 340 | 345 | 354 | 342 | 429 | 411 | 385 | 373 | 453 | 456 |
| Total Expenditure | 215 | 218 | 236 | 236 | 270 | 264 | 255 | 249 | 296 | 298 |
| Operating Profit | 125 | 127 | 118 | 106 | 158 | 148 | 129 | 124 | 157 | 157 |
| Interest | 13 | 14 | 17 | 18 | 18 | 18 | 18 | 18 | 19 | 20 |
| Depreciation | 27 | 28 | 32 | 34 | 35 | 35 | 34 | 34 | 36 | 40 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 85 | 85 | 69 | 53 | 105 | 94 | 77 | 71 | 102 | 98 |
| Provision for Tax | 22 | 22 | 18 | 14 | 26 | 25 | 20 | 18 | 27 | 24 |
| Profit After Tax | 63 | 63 | 51 | 40 | 79 | 69 | 57 | 54 | 76 | 74 |
| Adjustments | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1 |
| Profit After Adjustments | 63 | 62 | 51 | 40 | 79 | 69 | 56 | 53 | 75 | 73 |
| Adjusted Earnings Per Share | 6.2 | 6.1 | 5 | 3.9 | 7.8 | 6.8 | 5.5 | 5.3 | 7.4 | 7.1 |
| #(Fig in Cr.) | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 321 | 402 | 543 | 719 | 650 | 974 | 1174 | 1297 | 1516 | 1613 |
| Other Income | 11 | 10 | 8 | 10 | 10 | 19 | 31 | 37 | 51 | 54 |
| Total Income | 332 | 411 | 551 | 730 | 660 | 993 | 1204 | 1334 | 1567 | 1667 |
| Total Expenditure | 266 | 332 | 431 | 519 | 485 | 666 | 774 | 865 | 1022 | 1098 |
| Operating Profit | 66 | 79 | 120 | 211 | 175 | 327 | 430 | 469 | 545 | 567 |
| Interest | 3 | 4 | 6 | 48 | 46 | 56 | 58 | 63 | 77 | 75 |
| Depreciation | 22 | 28 | 37 | 69 | 73 | 83 | 90 | 112 | 138 | 144 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 41 | 47 | 78 | 93 | 56 | 187 | 282 | 295 | 330 | 348 |
| Provision for Tax | 10 | 11 | 20 | 38 | 16 | 49 | 69 | 77 | 86 | 89 |
| Profit After Tax | 31 | 36 | 58 | 55 | 40 | 139 | 212 | 218 | 244 | 261 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | -0 | -2 | -1 | -1 | -1 |
| Profit After Adjustments | 31 | 36 | 58 | 56 | 40 | 138 | 211 | 217 | 243 | 257 |
| Adjusted Earnings Per Share | 3.4 | 4 | 6.4 | 6.2 | 4.4 | 14.7 | 20.8 | 21.4 | 24 | 25.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 17% | 16% | 16% | 0% |
| Operating Profit CAGR | 16% | 19% | 21% | 0% |
| PAT CAGR | 12% | 21% | 35% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -13% | 16% | NA% | NA% |
| ROE Average | 18% | 21% | 20% | 17% |
| ROCE Average | 30% | 34% | 33% | 27% |
| #(Fig in Cr.) | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 329 | 362 | 416 | 405 | 446 | 603 | 1060 | 1259 | 1468 |
| Minority's Interest | 0 | 0 | 0 | 4 | 2 | 3 | 5 | 6 | 7 |
| Borrowings | 10 | 10 | 50 | 46 | 41 | 27 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 4 | 5 | 7 | 472 | 468 | 526 | 541 | 730 | 722 |
| Total Current Liabilities | 56 | 70 | 86 | 171 | 122 | 125 | 139 | 149 | 151 |
| Total Liabilities | 399 | 448 | 559 | 1098 | 1078 | 1284 | 1745 | 2144 | 2347 |
| Fixed Assets | 174 | 296 | 344 | 702 | 772 | 858 | 931 | 1253 | 1398 |
| Other Non-Current Assets | 100 | 79 | 78 | 153 | 109 | 136 | 336 | 270 | 127 |
| Total Current Assets | 126 | 73 | 136 | 244 | 197 | 290 | 478 | 622 | 822 |
| Total Assets | 399 | 448 | 559 | 1098 | 1078 | 1284 | 1745 | 2144 | 2347 |
| #(Fig in Cr.) | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 4 | 5 | 3 | 5 | 7 | 6 | 10 | 17 | 10 |
| Cash Flow from Operating Activities | 36 | 48 | 90 | 170 | 143 | 224 | 329 | 321 | 396 |
| Cash Flow from Investing Activities | -33 | -42 | -117 | -117 | -83 | -175 | -465 | -226 | -268 |
| Cash Flow from Financing Activities | -1 | -7 | 28 | -52 | -61 | -44 | 143 | -102 | -118 |
| Net Cash Inflow / Outflow | 1 | -2 | 2 | 2 | -1 | 4 | 7 | -7 | 10 |
| Closing Cash & Cash Equivalent | 5 | 3 | 5 | 7 | 6 | 10 | 17 | 10 | 20 |
| # | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 3.43 | 3.96 | 6.4 | 6.18 | 4.44 | 14.7 | 20.77 | 21.38 | 23.97 |
| CEPS(Rs) | 5.9 | 7.14 | 10.52 | 13.84 | 12.53 | 23.6 | 29.82 | 32.55 | 37.68 |
| DPS(Rs) | 2.5 | 1 | 1 | 2 | 0 | 2 | 3 | 3 | 3 |
| Book NAV/Share(Rs) | 35.24 | 38.93 | 44.88 | 43.77 | 48.32 | 62.93 | 104.42 | 123.08 | 144.41 |
| Core EBITDA Margin(%) | 17.1 | 17.3 | 20.61 | 27.9 | 25.4 | 31.61 | 34.05 | 33.34 | 32.6 |
| EBIT Margin(%) | 13.74 | 12.7 | 15.35 | 19.69 | 15.7 | 25.01 | 28.99 | 27.55 | 26.84 |
| Pre Tax Margin(%) | 12.84 | 11.64 | 14.3 | 12.98 | 8.57 | 19.24 | 24.01 | 22.73 | 21.77 |
| PAT Margin (%) | 9.76 | 9.03 | 10.67 | 7.69 | 6.09 | 14.24 | 18.1 | 16.83 | 16.11 |
| Cash Profit Margin (%) | 16.57 | 16.02 | 17.47 | 17.34 | 17.37 | 22.79 | 25.79 | 25.47 | 25.24 |
| ROA(%) | 7.86 | 8.57 | 11.51 | 6.68 | 3.64 | 11.74 | 14.02 | 11.23 | 10.87 |
| ROE(%) | 9.87 | 10.85 | 15.34 | 13.85 | 9.54 | 27 | 25.72 | 18.91 | 17.99 |
| ROCE(%) | 12.83 | 14.2 | 19.81 | 30.56 | 21.42 | 42.92 | 39.96 | 30.82 | 29.83 |
| Receivable days | 15.54 | 13.2 | 14.78 | 18.4 | 24.69 | 15.81 | 14.24 | 17.12 | 17.79 |
| Inventory Days | 7.65 | 5.78 | 4.36 | 5.83 | 7.32 | 4.67 | 5.22 | 6.01 | 6.21 |
| Payable days | 142.04 | 134.98 | 134.76 | 161.38 | 197.76 | 110.68 | 165.2 | 177.11 | 161.48 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 35.16 | 60.71 | 58.39 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 6.99 | 10.55 | 9.69 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0.41 | 0.23 | 0.21 |
| EV/Net Sales(x) | -0.16 | 0.08 | 0.06 | 0.02 | 0.01 | -0.04 | 6.28 | 10.15 | 9.36 |
| EV/Core EBITDA(x) | -0.8 | 0.41 | 0.25 | 0.06 | 0.03 | -0.12 | 17.11 | 28.04 | 26.03 |
| Net Sales Growth(%) | 0 | 25.07 | 35.08 | 32.54 | -9.64 | 49.8 | 20.52 | 10.51 | 16.88 |
| EBIT Growth(%) | 0 | 15.65 | 63.19 | 69.99 | -27.93 | 138.58 | 39.69 | 5.05 | 13.84 |
| PAT Growth(%) | 0 | 15.74 | 59.67 | -4.47 | -28.5 | 250.47 | 53.15 | 2.78 | 11.88 |
| EPS Growth(%) | 0 | 15.65 | 61.61 | -3.41 | -28.19 | 231.04 | 41.3 | 2.93 | 12.12 |
| Debt/Equity(x) | 0.05 | 0.04 | 0.12 | 0.14 | 0.1 | 0.07 | 0 | 0 | 0 |
| Current Ratio(x) | 2.26 | 1.03 | 1.58 | 1.42 | 1.61 | 2.32 | 3.44 | 4.16 | 5.46 |
| Quick Ratio(x) | 2.14 | 0.95 | 1.5 | 1.33 | 1.53 | 2.2 | 3.31 | 4 | 5.28 |
| Interest Cover(x) | 15.25 | 11.96 | 14.64 | 2.93 | 2.2 | 4.34 | 5.83 | 5.71 | 5.3 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 49.83 | 49.83 | 49.88 | 49.85 | 49.85 | 49.85 | 49.85 | 49.85 | 49.84 | 49.84 |
| FII | 22.32 | 24.04 | 24.78 | 25.11 | 25.12 | 23.69 | 23.59 | 21.85 | 19.23 | 17.24 |
| DII | 15.62 | 14.76 | 13.8 | 13.83 | 13.87 | 15.31 | 15.44 | 17.46 | 19.49 | 21.13 |
| Public | 12.23 | 11.37 | 11.54 | 11.2 | 11.16 | 11.14 | 11.11 | 10.84 | 11.44 | 11.79 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 | 5.06 |
| FII | 2.27 | 2.44 | 2.52 | 2.55 | 2.55 | 2.41 | 2.4 | 2.22 | 1.95 | 1.75 |
| DII | 1.59 | 1.5 | 1.4 | 1.4 | 1.41 | 1.56 | 1.57 | 1.77 | 1.98 | 2.15 |
| Public | 1.24 | 1.15 | 1.17 | 1.14 | 1.13 | 1.13 | 1.13 | 1.1 | 1.16 | 1.2 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10.15 | 10.15 | 10.15 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
